CN115279756A - Mettl3调节剂 - Google Patents

Mettl3调节剂 Download PDF

Info

Publication number
CN115279756A
CN115279756A CN202080086304.8A CN202080086304A CN115279756A CN 115279756 A CN115279756 A CN 115279756A CN 202080086304 A CN202080086304 A CN 202080086304A CN 115279756 A CN115279756 A CN 115279756A
Authority
CN
China
Prior art keywords
alkyl
independently selected
cycloalkyl
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080086304.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·韦恩
B·L·霍杜斯
P·A·博里阿克-斯霍丁
E·A·西克米尔
J·E·J·米尔斯
A·S·塔斯克
R·A·科普兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exent Therapeutics
Original Assignee
Exent Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exent Therapeutics filed Critical Exent Therapeutics
Publication of CN115279756A publication Critical patent/CN115279756A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080086304.8A 2019-10-25 2020-10-22 Mettl3调节剂 Pending CN115279756A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926072P 2019-10-25 2019-10-25
US62/926,072 2019-10-25
PCT/US2020/056873 WO2021081211A1 (en) 2019-10-25 2020-10-22 Mettl3 modulators

Publications (1)

Publication Number Publication Date
CN115279756A true CN115279756A (zh) 2022-11-01

Family

ID=73288712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080086304.8A Pending CN115279756A (zh) 2019-10-25 2020-10-22 Mettl3调节剂

Country Status (6)

Country Link
US (1) US20220372040A1 (OSRAM)
EP (1) EP4048670A1 (OSRAM)
JP (1) JP2022553376A (OSRAM)
CN (1) CN115279756A (OSRAM)
AU (1) AU2020370281A1 (OSRAM)
WO (1) WO2021081211A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204452A1 (en) * 2021-03-26 2022-09-29 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof
TW202321246A (zh) * 2021-07-20 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Prmt5抑制劑
CN116283993B (zh) * 2021-12-20 2024-05-03 艾立康药业股份有限公司 一种嘧啶类化合物及其制备方法和应用
EP4477654A4 (en) * 2022-02-11 2026-05-20 Xizang Haisco Pharmaceutical Co Ltd METTL3 INHIBITOR AND COMPOSITION, AND THEIR APPLICATION IN MEDICINE
KR102866487B1 (ko) 2023-01-06 2025-10-01 연세대학교 산학협력단 새로운 인돌리진-피롤로피리미딘 하이브리드 유도체 제조방법 및 이를 포함하는 항암제 조성물
US12091400B2 (en) 2023-01-20 2024-09-17 Epics Therapeutics Piperidine derivatives as METTL3 inhibitors
EP4688768A1 (en) 2023-03-30 2026-02-11 Novalix Novel mettl3 inhibitors and use thereof in therapy
US12168662B1 (en) 2023-12-15 2024-12-17 King Faisal University Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors
GB202407738D0 (en) * 2024-05-31 2024-07-17 Storm Therapeutics Ltd Inhibitory compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097648A1 (en) * 2006-02-24 2007-08-30 Industrial Research Limited Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
WO2019116302A1 (en) * 2017-12-13 2019-06-20 Lupin Limited Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2019197024A1 (en) * 2018-04-11 2019-10-17 Chemestmed Ltd. A method of modulating the rna methylation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097648A1 (en) * 2006-02-24 2007-08-30 Industrial Research Limited Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
WO2019116302A1 (en) * 2017-12-13 2019-06-20 Lupin Limited Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2019197024A1 (en) * 2018-04-11 2019-10-17 Chemestmed Ltd. A method of modulating the rna methylation

Also Published As

Publication number Publication date
WO2021081211A1 (en) 2021-04-29
US20220372040A1 (en) 2022-11-24
JP2022553376A (ja) 2022-12-22
EP4048670A1 (en) 2022-08-31
AU2020370281A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CN116262749B (zh) 一类芳杂环取代的化合物及其制备方法和用途
EP3814357B1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
CN107531695B (zh) Jak抑制剂
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
AU2020370281A1 (en) METTL3 modulators
AU2015276264B2 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
US9822124B2 (en) Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN113166156B (zh) 酪氨酸激酶抑制剂、组成及其方法
BR112019012993A2 (pt) derivados de benzo-oxazol como imunomoduladores
WO2013085802A1 (en) Pyrrolopyrimidines as janus kinase inhibitors
CN117355532A (zh) 三并环类usp1抑制剂及其用途
HUE035919T2 (en) Macrocyclic pyridazinone derivatives
CN115298179A (zh) Mettl3调节剂
CN112409385B (zh) 氮杂芳基化合物及其应用
WO2022204452A1 (en) Tead inhibitors and uses thereof
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
WO2018233527A1 (zh) 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
CN121013849A (zh) 作为wrn抑制剂的杂环化合物
CN117396485A (zh) Parp7抑制剂
CN118974033A (zh) Bcl-xL抑制剂
KR102130253B1 (ko) 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염
KR20240150419A (ko) 아릴설폰아미드 화합물
WO2025006293A2 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221101